Moloney Securities Asset Management LLC Invests $1.73 Million in GSK PLC Sponsored ADR (NYSE:GSK)

Moloney Securities Asset Management LLC acquired a new stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 44,679 shares of the pharmaceutical company's stock, valued at approximately $1,731,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Axxcess Wealth Management LLC purchased a new position in GSK during the 1st quarter worth $211,000. Rehmann Capital Advisory Group increased its position in GSK by 4.6% in the first quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock worth $248,000 after buying an additional 279 shares during the last quarter. Personal CFO Solutions LLC raised its position in shares of GSK by 5.6% in the first quarter. Personal CFO Solutions LLC now owns 12,377 shares of the pharmaceutical company's stock valued at $479,000 after purchasing an additional 653 shares during the period. Valeo Financial Advisors LLC boosted its holdings in GSK by 50.4% in the 1st quarter. Valeo Financial Advisors LLC now owns 12,601 shares of the pharmaceutical company's stock worth $488,000 after buying an additional 4,221 shares during the period. Finally, May Hill Capital LLC purchased a new position in GSK in the 1st quarter valued at approximately $365,000. 15.74% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on GSK shares. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, BNP Paribas started coverage on GSK in a report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $37.38.

GSK Stock Up 1.5%

GSK stock traded up $0.56 during midday trading on Wednesday, hitting $39.04. The stock had a trading volume of 3,624,171 shares, compared to its average volume of 4,941,822. The business has a 50-day moving average of $38.99 and a two-hundred day moving average of $37.18. The firm has a market cap of $79.93 billion, a price-to-earnings ratio of 20.12, a price-to-earnings-growth ratio of 1.53 and a beta of 0.50. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58. GSK PLC Sponsored ADR has a 52-week low of $31.72 and a 52-week high of $44.67.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The business had revenue of $10.06 billion during the quarter, compared to analysts' expectations of $7.52 billion. During the same quarter in the previous year, the business earned $0.43 earnings per share. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be issued a $0.4216 dividend. The ex-dividend date is Friday, May 16th. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.32%. GSK's payout ratio is 86.60%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.